Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms of GLT-1 deficiency may be a novel strategy for treating drug-resistant epilepsy, the underlying molecular cascade remains largely unknown. Here, we show that Hsp90β is up-regulated in reactive astrocytes of the epileptic hippocampus in patients with TLE and mouse models of epilepsy. Inhibition of Hsp90, but not Hsp70, increased GLT-1 levels. Mechanistically, Hsp90β recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradation. Hsp90 inhibitor prevents GLT-1 degradation by disrupting the association between Hsp90β and GLT-1. Using a model of TLE, we demonstrated that long-term systemic administration of 17AAG dramatically suppressed spontaneous recurrent seizures and ameliorated astrogliosis. Overall, these results suggest that up-regulation of GLT-1 by inhibiting Hsp90β in reactive astrocytes may be a potential therapeutic target for the treatment of epilepsy and excitotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · cited 1×
“Hsp90 is the most highly expressed cellular protein involved in the stabilization of other proteins and protein degradation under environmental stress (Whitesell and Lindquist, 2005).”
Backgroundβ-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 1×
“Rothstein et al. (2005) first discovered that many β-lactam antibiotics, such as ceftriaxone, can increase GLT-1 levels through transcriptional activation.”
Background17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M., & Sobue, G. (2005) · Nature Medicine · doi:10.1038/nm1298 · Cited by 395
Uhlmann, E. J., Wong, M., Baldwin, R. L., Bajenaru, M. L., Onda, H., Kwiatkowski, D. J., Yamada, K., & Gutmann, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10283 · Cited by 372 · cited 4×
“Astrocytespecific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures.”
MethodInfluentialLI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
Reactive Astrogliosis Causes the Development of Spontaneous Seizures
Robel, S., Buckingham, S. C., Boni, J. L., Campbell, S. L., Danbolt, N. C., Riedemann, T., Sutor, B., & Sontheimer, H. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1574-14.2015 · Cited by 283 · cited 2×
“Recent studies suggest that astrocytes are a potential target for the therapeutic treatment of intractable epilepsy (Héja, 2014; Robel et al., 2015).”
BackgroundSmall-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection
Kong, Q., Chang, L.-C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., Ibabao, B., Lin, Y., Stouffer, N., Mukhopadhyay, C. D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66163 · Cited by 156
Reelin deficiency causes granule cell dispersion in epilepsy
Haas, C. A., & Frotscher, M. (2010) · Experimental Brain Research · doi:10.1007/s00221-009-1948-5 · Cited by 96
Sha, L.-Z., Xing, X.-L., Zhang, D., Yao, Y., Dou, W.-C., Jin, L.-R., Wu, L.-W., & Xu, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039152 · Cited by 70
Self-citation
Cited by
Neuron–glia interactions in the pathophysiology of epilepsy
Patel, D. C., Tewari, B. P., Chaunsali, L., & Sontheimer, H. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0126-4 · Cited by 462
Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System
Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170
Green, J. L., dos Santos, W. F., & Fontana, A. C. K. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114786 · Cited by 150
HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling
Cheng, H.-M., Xing, M., Zhou, Y.-P., Zhang, W., Liu, Z., Li, L., Zheng, Z., Ma, Y., Li, P., Liu, X., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-022-01071-3 · Cited by 34
“HSP90 has been considered as a drug target for treating cancer [43], neurodegeneration diseases [44] and metabolic diseases [21, 45].”
Background
Metadata
- Authors
- Sha, L., Wang, X., Li, J., Shi, X., Wu, L., Shen, Y., & Xu, Q.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-12-27
- Volume
- 214
- Issue
- 2
- Pages
- 547-563
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2564814346
- Cited by
- 78
- References
- 9
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.